AUSTIN, Texas, July 1, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its Life ...
Luminex Corporation LMNX recently delivered the first of its new xMAP INTELLIFLEX Systems to several of its Life Science Research Partners. This marks a significant milestone in the company’s strategy ...
Meet xMAP® Technology all over again. Over the past 25 years, Luminex’s xMAP Technology has emerged as the worldwide leader in bead-based multiplexing. The new xMAP® INTELLIFLEX provides all of the ...
Luminex Corporation LMNX is well poised for growth backed by its solid molecular diagnostics, ARIES platforms and robust product portfolio. Shares of Luminex have gained 65.8%, compared with the ...
In preclinical proteomics, speed and accuracy are paramount. Increasingly, scientists must capture more data in less time while consuming minimal sample. Given the throughputs required for efficient ...
Errors in cell-signaling pathways play a central role in many diseases including cancer, diabetes, and autoimmune disorders. The ability to study these signaling pathways and accurately measure ...
Meet xMAP Technology all over again. Over the past 25 years, Luminex’s xMAP Technology has emerged as the worldwide leader in bead-based multiplexing. With the new xMAP INTELLIFLEX, we have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback